Association of serum pancreatic derived factor (PANDER) with beta-cell dysfunction in type 2 diabetes mellitus.
OBJECTIVE
Beta-cell dysfunction is the critical determinant for type 2 diabetes. The novel PANcreatic DERived factor (PANDER) has been identified as interesting islet-secreted cytokine that might be involved in beta-cell dysfunction, a role that has n"ot been clinically elucidated yet. Therefore, this study was designed to study the potential clinical association of this cytokine with beta-cell dysfunction in type 2 diabetes.


METHODS
Anthropometric parameters, routine biochemical markers and serum levels of PANDER were measured in 63 diabetic subjects including; recently diagnosed type 2 diabetic patients with duration of diabetes ≤6months and long-standing type 2 diabetic patients with duration of diabetes ≥5years then compared to 16 healthy control volunteers. Proinsulin, C-peptide, insulin and PANDER were measured by ELISA. Beta-cell dysfunction was assessed by HOMA2-%β, proinsulin, proinsulin-to-insulin (PI/I) ratio and proinsulin-to-C-peptide (PI/C-pep) ratio. Relations among various parameters were studied using simple and multiple linear regressions.


RESULTS
Serum PANDER levels were found to be significantly elevated in long-standing diabetics as compared to recently diagnosed diabetics and controls. In addition, PANDER was found to be significantly correlated negatively to HOMA2-%β, as well as positively to proinsulin, PI/I and PI/C-pep ratios.


CONCLUSIONS
PANDER is associated with beta-cell dysfunction in diabetic patients.
Biochemistry Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Miral M
MM
Shehata
Biochemistry Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Mohamed M
MM
Kamal
National institute of Diabetes and Endocrinology (NIDE), Cairo, Egypt.
Mohamed H
MH
El-Hefnawy
Biochemistry Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt. Electronic address: hala.elmesallamy@hotmail.com.
Hala O
HO
El-Mesallamy
D000465:Algorithms; D015415:Biomarkers / Q000097:blood; D002096:C-Peptide / Q000097:blood; D016207:Cytokines / Q000097:blood*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000378:metabolism* / Q000503:physiopathology; D018450:Disease Progression; D004534:Egypt; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006782:Hospitals, Special; D006801:Humans; D007328:Insulin / Q000097:blood / Q000378:metabolism*; D007333:Insulin Resistance; D000078790:Insulin Secretion; D050417:Insulin-Secreting Cells / Q000378:metabolism*; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000097:blood*; D010044:Outpatient Clinics, Hospital; D011384:Proinsulin / Q000097:blood; D015854:Up-Regulation
D015415:Biomarkers; D002096:C-Peptide; D016207:Cytokines; C577825:FAM3B protein, human; D007328:Insulin; D009363:Neoplasm Proteins; D011384:Proinsulin
Beta-cell dysfunction; HOMA-2%β; Islet-secreted cytokine; PANDER; Type 2 diabetes mellitus